Cargando…

Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker

The new and increasingly studied concept of immunogenic cell death (ICD) revealed a previously unknown perspective of the various regulated cell death (RCD) modalities, elucidating their immunogenic properties and rendering obsolete the notion that immune stimulation is solely the outcome of necrosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birmpilis, Anastasios I., Paschalis, Antonios, Mourkakis, Apostolis, Christodoulou, Panayiota, Kostopoulos, Ioannis V., Antimissari, Elina, Terzoudi, Georgia, Georgakilas, Alexandros G., Armpilia, Christina, Papageorgis, Panagiotis, Kastritis, Efstathios, Terpos, Evangelos, Dimopoulos, Meletios A., Kalbacher, Hubert, Livaniou, Evangelia, Christodoulou, Maria-Ioanna, Tsitsilonis, Ourania E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102069/ https://www.ncbi.nlm.nih.gov/pubmed/35563721 http://dx.doi.org/10.3390/cells11091415

Ejemplares similares

Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
por: Birmpilis, Anastasios I., et al.
Publicado: (2019)

Development of a specific IgY-based ELISA for prothymosin alpha, a bioactive polypeptide with diagnostic and therapeutic potential()
por: Karachaliou, Chrysoula-Evangelia, et al.
Publicado: (2019)

Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes
por: Ioannou, Kyriaki, et al.
Publicado: (2013)

Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells
por: Papadhimitriou, Stefanos I., et al.
Publicado: (2022)

A fragment of the alarmin prothymosin α as a novel biomarker in murine models of bacteria-induced sepsis
por: Samara, Pinelopi, et al.
Publicado: (2017)

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent
por: Papanagnou, Eleni-Dimitra, et al.
Publicado: (2018)

Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?
por: Samara, P., et al.
Publicado: (2016)

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection
por: Orologas-Stavrou, Nikolaos, et al.
Publicado: (2020)

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

Distinct type I interferon responses between younger women and older men contribute to the variability of COVID-19 outcomes: Hypothesis generating insights from COVID-19 convalescent individuals
por: Mavragani, Clio P., et al.
Publicado: (2022)

Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2018)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis
por: Kostopoulos, I V, et al.
Publicado: (2017)

P834: MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013)

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
por: Bagratuni, Tina, et al.
Publicado: (2020)

Aberrant Expression and Prognostic Potential of IL-37 in Human Lung Adenocarcinoma
por: Christodoulou, Panayiota, et al.
Publicado: (2022)

Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells
por: Skorda, Aikaterini, et al.
Publicado: (2019)

Amygdalin as a chemoprotective agent in co-treatment with cisplatin
por: Christodoulou, Panayiota, et al.
Publicado: (2022)

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
por: Malandrakis, Panagiotis, et al.
Publicado: (2023)

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
por: Terpos, Evangelos, et al.
Publicado: (2019)

Prothymosin α overexpression contributes to the development of pulmonary emphysema
por: Su, Bing-Hua, et al.
Publicado: (2013)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)

Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients
por: Melea, Pelagia I., et al.
Publicado: (2014)

Fascin-1 in Cancer Cell Metastasis: Old Target-New Insights
por: Sarantelli, Eleonora, et al.
Publicado: (2023)

Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis
por: Kumar, Anurag, et al.
Publicado: (2022)

Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection
por: Sfikakis, Petros P., et al.
Publicado: (2021)

EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic Targets
por: Stergiou, Ioanna E., et al.
Publicado: (2023)

Organ-specific manifestations of COVID-19 infection
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Common Genetic Aberrations Associated with Metabolic Interferences in Human Type-2 Diabetes and Acute Myeloid Leukemia: A Bioinformatics Approach
por: Kyriakou, Theodora-Christina, et al.
Publicado: (2021)

Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma.
por: Wu, C. G., et al.
Publicado: (1997)

Overexpression of Prothymosin Alpha Predicts Poor Disease Outcome in Head and Neck Cancer
por: Tripathi, Satyendra Chandra, et al.
Publicado: (2011)

Proteomic Analysis of Pichindé virus Infection Identifies Differential Expression of Prothymosin-α
por: Bowick, Gavin C., et al.
Publicado: (2010)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9m8o1937br4k4fr1gir94tnl2s